American Capital Management Inc. Raises Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

American Capital Management Inc. lifted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 2.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 380,646 shares of the company's stock after acquiring an additional 9,592 shares during the period. Medpace accounts for approximately 4.2% of American Capital Management Inc.'s holdings, making the stock its 5th biggest position. American Capital Management Inc. owned approximately 1.22% of Medpace worth $127,060,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Tidal Investments LLC boosted its stake in Medpace by 16.2% during the 1st quarter. Tidal Investments LLC now owns 874 shares of the company's stock valued at $353,000 after purchasing an additional 122 shares in the last quarter. Cetera Investment Advisers grew its holdings in Medpace by 235.0% during the first quarter. Cetera Investment Advisers now owns 11,494 shares of the company's stock worth $4,645,000 after acquiring an additional 8,063 shares during the period. Cetera Advisors LLC raised its position in Medpace by 162.4% in the first quarter. Cetera Advisors LLC now owns 2,608 shares of the company's stock worth $1,054,000 after acquiring an additional 1,614 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in Medpace by 3.4% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 36,030 shares of the company's stock valued at $14,459,000 after acquiring an additional 1,173 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Medpace by 58.4% in the 2nd quarter. GAMMA Investing LLC now owns 236 shares of the company's stock valued at $97,000 after acquiring an additional 87 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MEDP shares. Baird R W cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Robert W. Baird lifted their price target on shares of Medpace from $349.00 to $354.00 and gave the stock a "neutral" rating in a research report on Monday, November 25th. TD Cowen cut their price objective on Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Truist Financial decreased their target price on Medpace from $415.00 to $397.00 and set a "hold" rating on the stock in a report on Monday, October 14th. Finally, William Blair reaffirmed an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $380.56.

Medpace Trading Up 0.5 %

NASDAQ MEDP traded up $1.67 during trading on Friday, reaching $340.63. 214,814 shares of the company's stock were exchanged, compared to its average volume of 374,148. Medpace Holdings, Inc. has a fifty-two week low of $268.80 and a fifty-two week high of $459.77. The company's fifty day simple moving average is $337.82 and its 200-day simple moving average is $370.98. The firm has a market capitalization of $10.59 billion, a PE ratio of 29.83, a P/E/G ratio of 1.88 and a beta of 1.37.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping the consensus estimate of $2.77 by $0.24. The business had revenue of $533.32 million during the quarter, compared to analysts' expectations of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm's quarterly revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company posted $2.22 earnings per share. Equities analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.